Myeloma Steering Committee

The NCI Myeloma Steering Committee (MYSC) was established in 2009.  At monthly meetings, it addresses the design, prioritization, and evaluation of concepts for phase II and phase III clinical trials in adult myeloma. View the MYSC member roster as of May 30, 2024.

Strategic Priorities

• MYSC Strategic Priorities were formulated with the goal that the majority of submitted concepts would align with the established priorities. They address areas of unmet clinical need, important unanswered clinical questions, and potential new approaches to disease treatment.

Clinical Trial Planning Meetings (CTPMs)

CTPMs are held periodically and focus on specific clinical trial related topics. The following are important MYSC CTPMs:

• Strategies and Planning Working Group
  In May 2011, the MYSC convened a meeting to develop a working definition for high risk myeloma and share ideas for clinical trials, translational studies, and accrual issues for myeloma patients. Read the executive summary.

Contact

For more information, contact NCI CCCT Program Director, Elena Schwartz, Ph.D. at elena.schwartz@nih.gov.